Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hallucinogens Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

NCT01988311
View directory record Official record
Conditions
Psilocybin, Hallucinogens, Pharmacologic Actions, Central Nervous System Agents, Therapeutic Uses, Psychotropic Drugs
Interventions
psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 20, 2026, 5:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Hallucinogens and Other Drugs on Mood and Performance

NCT02033707
View directory record Official record
Conditions
Healthy
Interventions
Hallucinogens and psychoactive substances
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 20, 2026, 5:35 PM EDT
Enrolling by invitation Phase 3 Interventional

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

NCT06605105
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CYB003
Drug
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
18 Years to 85 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
42
States / cities
Phoenix, Arizona • Glendale, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 5:35 PM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy as a Treatment for Depression

NCT07582120
View directory record Official record
Conditions
Depression
Interventions
Psilocybin (Usona Institute)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 20, 2026, 5:35 PM EDT
Completed Not applicable Interventional

Low-Income Group Psilocybin Assisted Therapy for Depression

NCT06372197
View directory record Official record
Conditions
Depression
Interventions
Psilocybin
Drug
Lead sponsor
Matthew Hicks
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 20, 2026, 5:35 PM EDT
Completed Phase 2 Interventional

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

NCT05220410
View directory record Official record
Conditions
Treatment Resistant Depression, Suicidal Ideation
Interventions
Psilocybin
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 20, 2026, 5:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers

NCT05698095
View directory record Official record
Conditions
Pharmacokinetics, Safety, Tolerability
Interventions
5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo
Drug
Lead sponsor
Usona Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 20, 2026, 5:35 PM EDT
Completed Phase 1 Interventional

PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout

NCT05557643
View directory record Official record
Conditions
Depression, Burnout, Professional
Interventions
Psilocybin, Mindfulness-Based Stress Reduction (MBSR)
Drug · Behavioral
Lead sponsor
University of Utah
Other
Eligibility
25 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 20, 2026, 5:35 PM EDT
Terminated Phase 1 Interventional

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

NCT05322954
View directory record Official record
Conditions
Methamphetamine Use Disorder, Substance-Related Disorders, Chemically-Induced Disorders, Substance Use Disorders, Stimulant-Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
25 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 20, 2026, 5:35 PM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder

NCT07296094
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:35 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Neural and Physiological Correlates of Psychedelic Sub-states

NCT05698511
View directory record Official record
Conditions
Psychedelic Experiences, Neuroimaging, Healthy Volunteers
Interventions
Psilocybin
Drug
Lead sponsor
Robin Carhart-Harris, PhD, MA
Other
Eligibility
21 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 20, 2026, 5:35 PM EDT
Completed Phase 2 Interventional

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

NCT04661514
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Psilocybin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 20, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

A Study of Psilocybin for Major Depressive Disorder (MDD)

NCT03866174
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Psilocybin, Niacin, Set and Setting (SaS) Protocol
Drug · Other
Lead sponsor
Usona Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
San Francisco, California • Santa Monica, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 20, 2026, 5:35 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

MDMA-Assisted Therapy for Mental Healthcare Providers

NCT07102576
View directory record Official record
Conditions
Mental Wellbeing
Interventions
MDMA Hydrochloride
Drug
Lead sponsor
Rachel Yehuda
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 20, 2026, 5:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD

NCT05895318
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Not listed
Lead sponsor
Albany Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 20, 2026, 5:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot RECAP Study in Healthy Volunteers

NCT04842045
View directory record Official record
Conditions
Psychedelic Experiences, Amnesia
Interventions
Psilocybin and Midazolam
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 20, 2026, 5:35 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic

NCT04769297
View directory record Official record
Conditions
Acute Stress Disorder
Interventions
Sublingual Micro-Dose Ketamine
Drug
Lead sponsor
Limbic Medical
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Toluca Lake, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 20, 2026, 5:35 PM EDT
Recruiting Phase 2 Interventional

MDMA for Co-occurring PTSD and OUD After Childbirth

NCT05219175
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Opioid Use Disorder
Interventions
MDMA Assisted Therapy
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 20, 2026, 5:35 PM EDT
Enrolling by invitation Phase 1 Interventional

Psilocybin With Intracranial Neural Sensing

NCT06919640
View directory record Official record
Conditions
Chronic Pain
Interventions
Psilocybin
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 20, 2026, 5:35 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Psilocybin Microdosing on Cognition, Mood and Quality of Life

NCT07449351
View directory record Official record
Conditions
Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI
Interventions
Psliocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 5:35 PM EDT
Withdrawn Phase 2 Interventional

Trifecta Research Study

NCT06810765
View directory record Official record
Conditions
PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Trauma, Brain Injuries
Interventions
Hormone Replacement Therapy (HRT), Magnetic Resonance Therapy (MeRT), ibogaine with magnesium treatment, 5-MeO-DMT
Other · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 20, 2026, 5:35 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

NCT05385783
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CYB003, Psychotherapy, Placebo, Psychological Support
Drug · Behavioral
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
21 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 20, 2026, 5:35 PM EDT
Recruiting Phase 2 Interventional

A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

NCT06820723
View directory record Official record
Conditions
Depression, Anxiety, Major Depressive Disorder
Interventions
CYB003, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 5:35 PM EDT
Recruiting Early Phase 1 Interventional

Psilocybin for Methamphetamine Addiction

NCT06899594
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Psilocybin 25 mg
Drug
Lead sponsor
Kevin Murnane
Other
Eligibility
25 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 20, 2026, 5:35 PM EDT